Asahi Kasei has completed the acquisition of Aicuris Anti-infective Cures AG, marking a strategic step in strengthening its global pharmaceutical presence, particularly in the field of severe infectious diseases.

The acquisition brings a portfolio of three antiviral assets spanning commercial, near-term and pipeline-stage opportunities. These include a royalty-generating product, a late-stage candidate under regulatory review and a long-term development asset, offering a balanced mix of revenue streams and growth potential.

A key asset in the portfolio is pritelivir, currently under review by the U.S. Food and Drug Administration, with a decision expected in late 2026. The therapy targets immunocompromised patients, a segment with significant unmet medical needs. Another asset, AIC468, is being developed to treat BK virus infections in transplant patients, a growing area of clinical importance.

The acquisition also includes a royalty stream from an existing antiviral product, expected to generate substantial annual revenue depending on market performance. Combined, these assets are projected to help scale the acquired business to approximately USD 500 million in revenue by 2030.

Asahi Kasei plans to integrate Aicuris’s capabilities with its US-based subsidiary, Veloxis Pharmaceuticals, leveraging its expertise in transplant medicine, research and commercialisation to accelerate development and market access.

The move aligns with Asahi Kasei’s broader strategy to expand its healthcare segment and invest in high-growth pharmaceutical areas, while addressing critical treatment gaps for immunocompromised patients worldwide.